Effect of melatonin supplementation on cardiometabolic risk factors, oxidative stress and hormonal profile in PCOS patients: a systematic review and meta-analysis of randomized clinical trials.
Study Goal
To determine if melatonin supplementation improves cardiometabolic risk factors, oxidative stress, hormonal outcomes, and pregnancy-related factors in PCOS patients.
Results Summary
Melatonin significantly increased TAC levels, indicating antioxidant benefits, but its effects on cardiometabolic, hormonal, and pregnancy-related outcomes require further large-scale, long-term RCTs.
Population
Patients with polycystic ovary syndrome (PCOS).
Effective Dosage
Not specified
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
melatonin supplementation | increase | cardiometabolic risk factors | patients with PCOS | - | can enhance | #1 |
melatonin supplementation | decrease | oxidative stress | patients with PCOS | - | reduce | #2 |
melatonin supplementation | increase | hormonal and pregnancy-related factors | patients with PCOS | - | improve | #3 |
melatonin intake | increase | TAC levels | patients with polycystic ovary syndrome (PCOS) | SMD: 0.87, 95% CI: 0.46, 1.28 | significantly increase | #4 |
melatonin | decrease | oxidative stress | patients with PCOS | - | is a potential antioxidant that may prevent damage from | #5 |
BACKGROUND: To investigate whether melatonin supplementation can enhance cardiometabolic risk factors, reduce oxidative stress, and improve hormonal and pregnancy-related factors in patients with PCOS. METHODS: We conducted a systematic search of PubMed/Medline, Scopus, and the Cochrane Library for articles published in English from inception to March 2023. We included randomized controlled trials (RCTs) on the use of melatonin for patients with polycystic ovary syndrome (PCOS). We performed a meta-analysis using a random-effects model and calculated the standardized mean differences (SMDs) and 95% confidence intervals (CIs). RESULTS: Six studies met the inclusion criteria. The result of meta-analysis indicated that melatonin intake significantly increase TAC levels (SMD: 0.87, 95% CI: 0.46, 1.28, I CONCLUSION: Melatonin is a potential antioxidant that may prevent damage from oxidative stress in patients with PCOS. However, the clear effect of melatonin supplementation on cardiometabolic risk factors, hormonal outcomes, and pregnancy-related outcomes needs to be evaluated further in large populations and long-term RCTs.